ArticleNature clinical practice. Endocrinology & metabolism2009
Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?
Article in Nature clinical practice. Endocrinology & metabolism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This Practice Point commentary discusses the findings of the 10-year follow-up of the United Kingdom Prospective Diabetes Study, which was a multicenter, randomized, controlled trial in which patients with newly diagnosed type 2 diabetes mellitus received conventional or intensive glycemic control. The follow-up study by Holman et al. suggests that intensive glycemic control can have long-lasting benefits in reducing the incidence not only of diabetes-related end points and microvascular complications (as shown in the original UKPDS study) but also of myocardial infarction and death from any cause. These benefits occurred despite the early loss of within-trial differences in HbA(1c) levels between the intensive and conventional treatment groups. The findings of Holman et al. support the notion of a sustained, legacy effect of intensive glycemic control, which was originally suggested in the Epidemiology of Diabetes Interventions and Complications study.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.